Paper Details

  1. Home
  2. Paper Details

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

Author: AndreeffM, BeranM, CortesJ, EsteyE H, FreireichE, KantarjianH, KeatingM J, PierceS, ThallP F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a study of 215 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), adding all-trans retinoic acid (ATRA) and/or granulocyte colony-stimulating factor (G-CSF) to standard chemotherapy did not improve survival, time to relapse, or remission rates. While adding G-CSF to chemotherapy improved the chance of achieving remission, it had no impact on other outcomes. These findings suggest that ATRA and G-CSF are not effective additions to chemotherapy for these patients.
Paper Details　
Original Abstract of the Article :
Preclinical data suggest that retinoids, eg, all-trans retinoic acid (ATRA), lower concentrations of antiapoptotic proteins such as bcl-2, possibly thereby improving the outcome of anti-acute myeloid leukemia (AML) chemotherapy. Granulocyte colony-stimulating factor (G-CSF) has been considered to be...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10194425

データ提供：米国国立医学図書館（NLM）

Exploring New Treatment Strategies for Acute Myeloid Leukemia

The world of hematology is a complex desert, where we strive to find effective treatments for blood cancers, like acute myeloid leukemia (AML). This research explores the potential of combining fludarabine, cytosine arabinoside, and idarubicin with all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) in patients with poor-prognosis, newly diagnosed AML or high-risk myelodysplastic syndrome (MDS). The authors conducted a randomized phase II study to evaluate the efficacy of these treatment combinations.

The Quest for Improved Outcomes

The study found that the addition of ATRA and G-CSF to the standard fludarabine, cytosine arabinoside, and idarubicin regimen did not significantly improve survival, event-free survival, or event-free survival once in complete remission in patients with poor-prognosis, newly diagnosed AML or high-risk MDS. This finding suggests that these agents may not be beneficial in this patient population.

Navigating the Treatment Landscape for AML

This research highlights the need for continued research into new and effective treatments for AML. While the combination of ATRA and G-CSF did not demonstrate significant benefits in this study, it is essential to continue exploring new therapeutic strategies to improve outcomes for patients with this challenging disease. As we journey through the desert of hematological research, we must persevere in our quest to find new oases of hope for those battling blood cancers.

Dr.Camel's Conclusion

This research provides valuable insights into the treatment of poor-prognosis, newly diagnosed AML and high-risk MDS. While the addition of ATRA and G-CSF to the standard regimen did not yield significant benefits, the authors underscore the need for ongoing research into new and effective therapies for this challenging disease.

Date :
  1. Date Completed 1999-05-03
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

10194425

DOI: Digital Object Identifier

S0006-4971(20)48931-1

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.